All In Biotech

Drug Trial Radar · NCT07891416

Phase II Clinical Study on Preliminary Efficacy and Safety of ETD-001 Gel for Hypertrophic Scars

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Preliminary Efficacy and Safety of ETD-001 Gel for the Treatment of Hypertrophic Scars

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Feb 28, 2027

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Etern Therapeutics Wuxi LimitedAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled multiple dosing study to evaluate the preliminary efficacy and safety of ETD-001 gel for hypertrophic scars. Subjects will be assigned to 3 groups: ETD-001 Dose Group 1, ETD-001 Dose Group 2, and placebo group.

Conditions

  • Hypertrophic Scars

Interventions

  • ETD-001 gelDrug

    Topical investigational gel, multiple daily application on hypertrophic scar lesions for scheduled treatment period.

  • ETD-001 gelDrug

    Topical investigational gel (higher concentration), multiple daily application on hypertrophic scar lesions for scheduled treatment period.

  • PlaceboOther

    Matched topical placebo gel, identical appearance and administration regimen, applied on hypertrophic scar lesions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Evaluate the Preliminary Efficacy of ETD-001 Gel in the Treatment of Hypertrophic Scars :Change from Baseline in Modified Vancouver Scar Scale (mVSS) ScoreTime frame: 4~12weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.